Core Viewpoint - The report provides a detailed account of the fundraising activities and the usage of funds by 博瑞生物医药 (Suzhou) Co., Ltd. as of June 30, 2025, highlighting the amounts raised, their allocation, and the management of these funds [1][2][3]. Fundraising Overview - The company raised a total of RMB 521.11 million from its initial public offering (IPO) in 2019, with a net amount of RMB 439.98 million after deducting various fees [1]. - In 2022, the company issued convertible bonds amounting to RMB 465 million, resulting in a net amount of RMB 456.83 million after fees [2]. - The company also raised RMB 226.61 million through a private placement of shares in November 2022, with the net amount after fees not specified [2]. Fund Management - The company established a dedicated account for managing the raised funds, ensuring that the funds are used specifically for their intended purposes [3]. - A tripartite supervision agreement was signed with the underwriter and banks to oversee the management of the funds [3]. Fund Usage and Balance - As of June 30, 2025, the total amount of funds used from the IPO was RMB 455.75 million, with a remaining balance of RMB 0.00 million [5]. - For the convertible bonds, RMB 466.75 million was used, leaving no remaining balance [5]. - From the private placement, RMB 188.74 million was utilized, with a remaining balance of RMB 3.64 million [13]. Project Adjustments - The company did not make any adjustments to the investment amounts for the projects funded by the IPO as of June 30, 2025 [5]. - The overseas high-end formulation drug production project was delayed, with the expected completion date pushed from December 2021 to June 2023 due to various factors including the pandemic [5]. - The company has also changed the implementation entities for some projects to improve management efficiency [5]. Temporary Idle Funds - The company has not used idle funds to temporarily supplement working capital as of June 30, 2025 [8]. - The company has engaged in cash management for temporarily idle funds, generating a total return of RMB 15.62 million from such activities [10][12].